Inhibiting RANK-signaling by an existing monoclonal antibody (i.e., denosumab) to simultaneously prevent breast cancer and maintain bone health (particularly after salpingo-oophorectomy) represents an important opportunity that warrants exploration in a primary prevention trial of BRCA mutation carriers. This evidence concerns the gene TNFRSF11A and breast cancer.